Harvard College

Dana-Farber-Cancer Institute Inc.

Whitehead Institute for Biomedical Research

The General Hospital Corporation

The Broad Institute, Inc.

Alexander Meissner

Rudolf Jaenisch

Ruth Foreman

G Grant Welstead

Yaqub Hanna

Marius Wernig

Christopher J Lengner

Oliver Tobias Brambrink

Catherine Ju-Ying Wu

Gad Getz

Veronika Akopian

Mark Kendell Clement

Alexander Tsankov

Dan-Avi Landau

Jacob Hanna

Franziska Michor

Jiantao Shi

Zachary D Smith

Rudolph Jaenisch

Methods for quantifying DNA methylation that may be utilized for screening for diseases (e.g., cancer), diagnosing diseases (e.g., cancer type), monitoring progression of a disease, and monitoring response to a therapeutic treatment.

Universal early cancer diagnostics

The present invention relates to methods of determining a cancer treatment prognosis for a subject in need thereof by evaluating epigenetic and genetic changes within a tumor sample from the subject. The present invention further provides methods of treating cancer in a subject by evaluating epigenetic and genetic changes within a tumor sample from the subject. In addition, the present invention provides methods of screening test agents to identify agents that decrease tumor cell plasticity.

Compositions and methods for diagnosing, evaluating and treating cancer by means of the DNA methylation status

The present invention generally relates to a set of early developmental reference data or 'lineage scorecard' for stem cells, and methods, systems and kits to generate a lineage scorecard for predicting the functionality and suitability of stem cell lines. In some aspects, methods for generating a scorecard comprises measuring the gene expression of a plurality of early developmental genes, such as pluripotent, early ectoderm, early mesoderm and early endoderm genes to predict the pluripotency and differentiation potential of the stem cell line and its functionality and/or suitability for a desired use. In some embodiments, a reference scorecard can be compared with the test stem cell line scorecard to accurately predict the utility and/or identify specific characteristics of the stem cell line, e.g., to determine its suitability for downstream applications, e.g., therapeutic use, drug screening, toxicity assays, differentiation into a desired cell lineage, etc.

Early developmental genomic assay for characterizing pluripotent stem cell utility and safety

Compositions and methods for diagnosing, evaluating and treating cancer

The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.

Reprogramming of somatic cells

Growing community of inventors

Cambridge, MA, United States of America

Alexander Meissner